18.66
price down icon2.96%   -0.57
after-market After Hours: 18.41 -0.25 -1.34%
loading
Summit Therapeutics Inc stock is traded at $18.66, with a volume of 3.79M. It is down -2.96% in the last 24 hours and down -11.81% over the past month. Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
See More
Previous Close:
$19.23
Open:
$19.34
24h Volume:
3.79M
Relative Volume:
0.97
Market Cap:
$13.86B
Revenue:
$220.00K
Net Income/Loss:
$-746.08M
P/E Ratio:
-18.52
EPS:
-1.0074
Net Cash Flow:
$-211.81M
1W Performance:
-2.61%
1M Performance:
-11.81%
6M Performance:
-21.00%
1Y Performance:
-14.52%
1-Day Range:
Value
$18.38
$19.34
1-Week Range:
Value
$18.38
$20.24
52-Week Range:
Value
$15.55
$36.91

Summit Therapeutics Inc Stock (SMMT) Company Profile

Name
Name
Summit Therapeutics Inc
Name
Phone
305-203-2034
Name
Address
601 BRICKELL KEY DRIVE, MIAMI
Name
Employee
159
Name
Twitter
@summitplc
Name
Next Earnings Date
2025-10-20
Name
Latest SEC Filings
Name
SMMT's Discussions on Twitter

Compare SMMT with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
SMMT
Summit Therapeutics Inc
18.66 14.32B 220.00K -746.08M -211.81M -1.0074
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
417.21 108.30B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
652.91 69.37B 14.25B 4.58B 3.56B 41.77
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
481.59 62.38B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
ARGX
Argen X Se Adr
821.97 51.50B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
INSM
Insmed Inc
166.95 34.94B 398.11M -1.03B -868.57M -5.7032

Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades

Date Action Analyst Rating Change
Sep-17-25 Initiated Barclays Underweight
Sep-04-25 Initiated Guggenheim Buy
Aug-19-25 Initiated Piper Sandler Neutral
Jul-01-25 Initiated UBS Buy
Jun-11-25 Initiated Leerink Partners Underperform
Mar-26-25 Upgrade Citigroup Neutral → Buy
Mar-21-25 Initiated Cantor Fitzgerald Overweight
Mar-12-25 Initiated Evercore ISI Outperform
Feb-28-25 Initiated Goldman Buy
Jan-08-25 Initiated Truist Buy
Dec-11-24 Initiated Wells Fargo Overweight
Dec-06-24 Initiated Jefferies Buy
Nov-04-24 Initiated JMP Securities Mkt Outperform
Sep-27-24 Downgrade Citigroup Buy → Neutral
Aug-12-24 Initiated H.C. Wainwright Buy
May-07-24 Initiated Citigroup Buy
Mar-26-24 Initiated Stifel Buy
Jun-28-18 Downgrade Janney Buy → Neutral
May-02-18 Initiated Janney Buy
Apr-12-18 Reiterated Needham Buy
Feb-13-18 Initiated BTIG Research Buy
Jan-04-18 Initiated SunTrust Buy
Dec-01-17 Resumed H.C. Wainwright Buy
Nov-16-16 Reiterated RBC Capital Mkts Outperform
Oct-05-16 Reiterated Needham Buy
Sep-16-16 Initiated H.C. Wainwright Buy
Mar-30-15 Initiated Needham Buy
Mar-30-15 Initiated Oppenheimer Outperform
View All

Summit Therapeutics Inc Stock (SMMT) Latest News

pulisher
07:33 AM

What institutional flow reveals about Summit Therapeutics Inc.Market Sentiment Summary & Risk Adjusted Buy/Sell Alerts - newser.com

07:33 AM
pulisher
04:26 AM

Is Summit Therapeutics Inc. showing signs of accumulationJuly 2025 Sentiment & Community Trade Idea Sharing - newser.com

04:26 AM
pulisher
01:52 AM

Is Summit Therapeutics Inc. stock reversal real or fakeJuly 2025 Intraday Action & AI Forecasted Entry/Exit Points - newser.com

01:52 AM
pulisher
12:33 PM

Patterns Watch: Is Summit Therapeutics Inc. stock a safe haven asset2025 Volume Leaders & Weekly High Return Stock Forecasts - Fundação Cultural do Pará

12:33 PM
pulisher
Oct 28, 2025

Applying sector rotation models to Summit Therapeutics Inc.Portfolio Gains Report & Proven Capital Preservation Methods - newser.com

Oct 28, 2025
pulisher
Oct 28, 2025

Co-CEO & Executive Chairman of Summit Therapeutics Picks Up 2.5% More Stock - simplywall.st

Oct 28, 2025
pulisher
Oct 28, 2025

Co-CEO & Executive Chairman of Summit Therapeutics Robert Duggan Buys 2.5% More Shares - Yahoo Finance

Oct 28, 2025
pulisher
Oct 28, 2025

Insider Spends US$262m Buying More Shares In Summit Therapeutics - 富途牛牛

Oct 28, 2025
pulisher
Oct 28, 2025

Analyzing Summit Therapeutics Inc. with risk reward ratio charts2025 Performance Recap & Weekly High Momentum Picks - newser.com

Oct 28, 2025
pulisher
Oct 28, 2025

What margin trends mean for Summit Therapeutics Inc. stock2025 Top Decliners & Fast Exit/Entry Strategy Plans - Fundação Cultural do Pará

Oct 28, 2025
pulisher
Oct 27, 2025

Can Summit Therapeutics Inc. hit a new high this month2025 Winners & Losers & Low Risk Entry Point Guides - newser.com

Oct 27, 2025
pulisher
Oct 27, 2025

Should you hold or exit Summit Therapeutics Inc. nowRecession Risk & AI Based Trade Execution Alerts - newser.com

Oct 27, 2025
pulisher
Oct 27, 2025

Summit Therapeutics proves InvestingPro’s Fair Value accuracy with 40% return By Investing.com - Investing.com South Africa

Oct 27, 2025
pulisher
Oct 27, 2025

1 Monster Stock in the Making to Buy and Hold - Yahoo Finance

Oct 27, 2025
pulisher
Oct 27, 2025

News impact scoring models applied to Summit Therapeutics Inc.Fed Meeting & Risk Managed Investment Strategies - newser.com

Oct 27, 2025

Summit Therapeutics Inc Stock (SMMT) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$36.67
price up icon 0.71%
$90.18
price down icon 1.60%
$28.95
price down icon 0.62%
$103.35
price down icon 1.60%
biotechnology ONC
$314.85
price down icon 0.63%
$166.95
price up icon 1.00%
Cap:     |  Volume (24h):